VALSARTAN AND HYDROCHLOROTHIAZIDE tablet, film coated

Land: Vereinigte Staaten

Sprache: Englisch

Quelle: NLM (National Library of Medicine)

Wirkstoff:

VALSARTAN (UNII: 80M03YXJ7I) (VALSARTAN - UNII:80M03YXJ7I), HYDROCHLOROTHIAZIDE (UNII: 0J48LPH2TH) (HYDROCHLOROTHIAZIDE - UNII:0J48LPH2TH)

Verfügbar ab:

DirectRX

INN (Internationale Bezeichnung):

VALSARTAN

Zusammensetzung:

VALSARTAN 80 mg

Verabreichungsweg:

ORAL

Verschreibungstyp:

PRESCRIPTION DRUG

Anwendungsgebiete:

- Valsartan and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Educat

Berechtigungsstatus:

Abbreviated New Drug Application

Fachinformation

VALSARTAN AND HYDROCHLOROTHIAZIDE- VALSARTAN AND HYDROCHLOROTHIAZIDE
TABLET,
FILM COATED
DIRECTRX
----------
VALSARTAN AND HYDROCHLOROTHIAZIDE
INDICATIONS & USAGE SECTION
Valsartan and hydrochlorothiazide tablets, USP are indicated for the
treatment of hypertension, to
lower blood pressure. Lowering blood pressure reduces the risk of
fatal and nonfatal
cardiovascular events, primarily strokes and myocardial infarctions.
These benefits have been seen
in controlled trials of antihypertensive drugs from a wide variety of
pharmacologic classes,
including hydrochlorothiazide and the ARB class to which valsartan
principally belongs. There are
no controlled trials demonstrating risk reduction with valsartan and
hydrochlorothiazide tablets,
USP.
Control of high blood pressure should be part of comprehensive
cardiovascular risk management,
including, as appropriate, lipid control, diabetes management,
antithrombotic therapy, smoking
cessation, exercise, and limited sodium intake. Many patients will
require more than one drug to
achieve blood pressure goals. For specific advice on goals and
management, see published
guidelines, such as those of the National High Blood Pressure
Education Program’s Joint National
Committee on Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic
classes and with different
mechanisms of action, have been shown in randomized controlled trials
to reduce cardiovascular
morbidity and mortality, and it can be concluded that it is blood
pressure reduction, and not some
other pharmacologic property of the drugs, that is largely responsible
for those benefits. The
largest and most consistent cardiovascular outcome benefit has been a
reduction in the risk of stroke,
but reductions in myocardial infarction and cardiovascular mortality
also have been seen regularly.
Elevated systolic or diastolic pressure causes increased
cardiovascular risk, and the absolute risk
increase per mmHg is greater at higher blood pres